Insights from 2023 EHA® Annual Meeting

 

Insights from 2023 EHA® Annual Meeting
R

EHA® 2023 Insights: "Preliminary Results From the Ph1/2 RUBY Trial of EDIT-301 in Patients With Severe Sickle Cell Disease Using Highly Specific and Efficient ASCAS12A Enzyme"

By Insights from 2023 EHA® Annual Meeting FEATURING Rabi Hanna
By Insights from 2023 EHA® Annual Meeting FEATURING Rabi Hanna
188 views
June 23, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Benign Hematology
14:32

EHA® 2023 Insights: "Preliminary Results From the Ph1/2 RUBY Trial o…

Insights from 2023 EHA® Annual Meeting

R. Hanna

188 views
07:48

EHA® 2023 Insights: "ATLAS-PPX, A Ph3 Study of Fitusiran in People W…

Insights from 2023 EHA® Annual Meeting

G. Young

63 views